Bausch + Lomb: 3 key takeaways for long-term investors
Premium product adoption is lifting margins faster than revenue growth, a sign of pricing power in a competitive market.
Model output · Signal date 2026-11-06
Bausch & Lomb Corp (BLCO) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
27.0%
Spearman, 357 dates
Market Cap
$7.15B
mid-cap · #3 of 8 peers
Summary
Bausch & Lomb Corp (BLCO) stock forecast summary
Our AI scores Bausch & Lomb Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Bausch & Lomb Corp is a mid-cap company with a market capitalization of $7.15B. It ranks number 3 by market capitalization among the 8 Ophthalmic Goods issuers in our coverage with a current forecast.
For BLCO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 27.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 14.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BLCO included.
Price
BLCO price chart and AI forecast
Cross-section · 2026-11-06
How BLCO ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Bausch & Lomb Corp (BLCO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Ophthalmic Goods peers listed below that report each metric.
Valuation & Market
| Metric | BLCO | Rank |
|---|---|---|
| Market Cap | $7.15B | 3/8 |
| P/B Ratio | 1.11x | 5/7 |
| EPS | $-0.85 | – |
| Book Value/Share | $18.01 | – |
| Revenue/Share | $15.16 | – |
| FCF/Share | $0.70 | – |
Profitability & Margins
| Metric | BLCO | Rank |
|---|---|---|
| ROIC | 3.2% | 3/5 |
| Operating Margin | 7.1% | 2/6 |
| EBT Margin | -0.1% | 5/6 |
| Tax Rate | -2475.0% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | BLCO | Rank |
|---|---|---|
| Current Ratio | 1.56x | 5/7 |
| Quick Ratio | 1.04x | 5/7 |
| D/E Ratio | 1.16x | 2/8 |
| Financial Leverage | 2.17x | 2/6 |
| Interest Coverage | 1.6x | 4/6 |
| Working Capital | $1.09B | 1/7 |
Cash Flow
| Metric | BLCO | Rank |
|---|---|---|
| Operating Cash Flow | $554M | 2/7 |
| Free Cash Flow | $252M | 2/6 |
| Capital Spending | -$302M | 5/6 |
| OCF Growth YoY | 227.8% | – |
| FCF/Sales | 4.7% | 4/6 |
| CapEx/Sales | 5.6% | 3/6 |
Operational Efficiency
| Metric | BLCO | Rank |
|---|---|---|
| Asset Turnover | 0.39x | 4/6 |
| Receivables Turnover | 4.7x | 6/7 |
| Fixed Assets Turnover | 3.0x | 6/7 |
| Days Sales Outstanding | 77 days | 2/7 |
Income Statement
| Metric | BLCO | Rank |
|---|---|---|
| Total Revenue | $5.42B | 2/8 |
| Operating Income | $383M | 2/6 |
| R&D Expense | $400M | 1/5 |
| SG&A Expense | $2.25B | 2/8 |
Dividend & Shareholder Information
| Metric | BLCO | Rank |
|---|---|---|
| Shares Outstanding | 358M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3.06B | 21.9% of assets |
| Cash & Short-term Investments | $513M | 3.7% of assets |
| Accounts Receivable | $1.15B | 8.2% of assets |
| Inventory | $1.01B | 7.2% of assets |
| Total Liabilities | $7.45B | 53.4% of assets |
| Short-term Debt | $1.59B | 11.4% of assets |
Quarterly Financial Reports
BLCO quarterly financials and insider trading
Industry Peers · Ophthalmic Goods
Bausch & Lomb Corp (BLCO) industry peers
Companies classified under the same SEC industry code as Bausch & Lomb Corp (Ophthalmic Goods): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere BLCO sits on the market map
Industrial Applications and Services · Ophthalmic Goods
News
Bausch & Lomb Corp (BLCO) stock news
Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ...
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of ...
FAQ
Bausch & Lomb Corp (BLCO) stock forecast FAQ
What is the Bausch & Lomb Corp (BLCO) stock forecast?
Our AI scores Bausch & Lomb Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Bausch & Lomb Corp stock predictions?
For BLCO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 27.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 14.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Bausch & Lomb Corp forecasts updated?
Bausch & Lomb Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Bausch & Lomb Corp's industry peers?
8 issuers in our coverage, BLCO included, share the SEC industry code Ophthalmic Goods. The largest are: Alcon Inc (ALC), Cooper Companies, Inc. (COO), Warby Parker Inc. (WRBY), National Vision Holdings, Inc. (EYE), Staar Surgical Co (STAA), Rxsight, Inc. (RXST).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.